German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Here are the G-BA decisions from the G-BA meeting held on 19 October 2023 on the early benefit assessments of Hemgenix, Libtayo, Rinvoq, Talvey, and Adakveo. A complete database of all previous G-BA resolutions is available through my membership. Hemgenix (etranacogene dezaparvovec): Hemophilia B – Orphan drug, Hint of not-quantifiable additional benefit Libtayo (cemiplimab); new indication: cervical cancer,…
Here are the G-BA decisions from the G-BA meeting held on 5 October 2023 on the early benefit assessments of Imfinzi, Imjudo, Dupixent, Rayvow, Sotyktu, Ebvallo and Blenrep. A complete database of all previous G-BA resolutions is available through my membership. Imfinzi (durvalumab); new indication: Biliary tumours, first line, in combination with gemcitabine and cisplatin – Indication…
Here are the G-BA decisions from the G-BA meeting held on 21 September 2023 on the early benefit assessments of Nubeqa, Spravato, Reblozyl, Wakix, Dupixent, Trulicity, Lynparza, Rubraca, Ondexxya and Ultomiris. A complete database of all previous G-BA resolutions is available through my membership. Nubeqa (darolutamide); new indication: prostate cancer, metastatic, hormone-sensitive, combination with docetaxel and…
Here are the G-BA decisions from the G-BA meeting held on 17 August 2023 on the early benefit assessments of Carvykti, Hemlibra, Forxiga, Triumeq, Kerendia and Lupkynis. A complete database of all previous G-BA resolutions is available through my membership. Carvykti (ciltacabtagen autoleucel); relapsed / refractory multiple myeloma, after at least 3 previous therapies – Orphan drug,…
Here are the G-BA decisions from the G-BA meeting held on 3 August 2023 on the early benefit assessments of Fintepla and Lumykras. A complete database of all previous G-BA resolutions is available through my membership. Fintepla (fenfluramine); new indication: Lennox-Gastaut syndrome, add-on therapy, patients aged ≥ 2 years – Orphan drug, Hint of considerable additional benefit…
Here are the G-BA decisions from the G-BA meeting held on 20 July 2023 on the early benefit assessments of Enhertu, Imbruvica, Spevigo, Rapiscan, brexucabtagen autoleucel and autologous CD-19 cells. A complete database of all previous G-BA resolutions is available through my membership. Enhertu (trastuzumab deruxtecan); new indication: adenocarcinoma of the stomach or esophagogastric junction, HER2+,…
Here are the G-BA decisions from the G-BA meeting held on 12 May 2023 on the early benefit assessments of Tezpire, Adtralza and Quviviq. A complete database of all previous G-BA resolutions is available through my membership. Tezpire (tezepelumab); bronchial asthma, patients aged ≥ 12 years – For both subgroups, additional benefit not proven Adtralza…
Here are the G-BA decisions from the G-BA meeting held on 20 April 2023 on the early benefit assessments of Ultomiris, Genvoya, Lynparza, and Evusheld. A complete database of all previous G-BA resolutions is available through my membership. Ultomiris (ravulizumab); new indication: Myasthenia gravis, AChR antibodies+ – Additional benefit not proven; resolution restricted until 1 Nov 2023…